A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease
Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin ( HTT ) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functi...
Uloženo v:
| Vydáno v: | Journal of neuroinflammation Ročník 19; číslo 1; s. 56 - 17 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
26.02.2022
BioMed Central Ltd BMC |
| Témata: | |
| ISSN: | 1742-2094, 1742-2094 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the
huntingtin
(
HTT
) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer’s disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD.
Methods
To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human
HTT
gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice.
Results
Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice.
Conclusions
Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. |
|---|---|
| AbstractList | Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer's disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD.
To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice.
Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice.
Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1[beta] and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer's disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD. To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 [+ or -] 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice. Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1[beta] and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice. Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. Background Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1[beta] and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer's disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD. Methods To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 [+ or -] 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice. Results Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1[beta] and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice. Conclusions Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. Keywords: Huntington's disease (HD), Interleukin-1[beta] (IL-1[beta]), Mutated huntingtin (mHTT), Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer's disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD.BACKGROUNDHuntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer's disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD.To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice.METHODSTo evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice.Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice.RESULTSSystematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice.Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease.CONCLUSIONSCollectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin ( HTT ) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer’s disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD. Methods To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice. Results Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice. Conclusions Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. Abstract Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP3 inflammasome in HD remain largely uncharacterized. MCC950 is a highly selective and potent small-molecule inhibitor of NLRP3 that has been used for the treatment of several diseases such as Alzheimer’s disease. However, whether MCC950 is also beneficial in HD remains unknown. Therefore, we hypothesized that MCC950 exerts beneficial effects in a transgenic mouse model of HD. Methods To evaluate the effects of MCC950 in HD, we used the R6/2 (B6CBA-Tg[HDexon1]62Gpb/1J) transgenic mouse model of HD, which expresses exon 1 of the human HTT gene carrying 120 ± 5 CAG repeats. Male transgenic R6/2 mice were treated daily with MCC950 (10 mg/kg of body weight; oral administration) or water for 5 weeks from the age of 7 weeks. We examined neuronal density, neuroinflammation, and mHTT aggregation in the striatum of R6/2 mice vs. their wild-type littermates. We also evaluated the motor function, body weight, and lifespan of R6/2 mice. Results Systematic administration of MCC950 to R6/2 mice suppressed the NLRP3 inflammasome, decreased IL-1β and reactive oxygen species production, and reduced neuronal toxicity, as assessed based on increased neuronal density and upregulation of the NeuN and PSD-95 proteins. Most importantly, oral administration of MCC950 increased neuronal survival, reduced neuroinflammation, extended lifespan, and improved motor dysfunction in R6/2 mice. Conclusions Collectively, our findings indicate that MCC950 exerts beneficial effects in a transgenic mouse model of HD and has therapeutic potential for treatment of this devastating neurodegenerative disease. |
| ArticleNumber | 56 |
| Audience | Academic |
| Author | Lin, Ting-Yu Ju, Tz-Chuen Cheng, Chih-Yuan Yang, Ding-I. Tsai, Fu-Ting Hsu, Hsien-Ta Chen, Kai-Po Hua, Kuo-Feng |
| Author_xml | – sequence: 1 givenname: Kai-Po surname: Chen fullname: Chen, Kai-Po organization: Department of Animal Science and Biotechnology, Tunghai University – sequence: 2 givenname: Kuo-Feng surname: Hua fullname: Hua, Kuo-Feng organization: Department of Biotechnology and Animal Science, National Ilan University, Department of Medical Research, China Medical University Hospital, China Medical University – sequence: 3 givenname: Fu-Ting surname: Tsai fullname: Tsai, Fu-Ting organization: Department of Animal Science and Biotechnology, Tunghai University – sequence: 4 givenname: Ting-Yu surname: Lin fullname: Lin, Ting-Yu organization: Department of Animal Science and Biotechnology, Tunghai University – sequence: 5 givenname: Chih-Yuan surname: Cheng fullname: Cheng, Chih-Yuan organization: Department of Animal Science and Biotechnology, Tunghai University – sequence: 6 givenname: Ding-I. surname: Yang fullname: Yang, Ding-I. organization: Institute of Brain Science and Brain Research Center, National Yang Ming Chiao Tung University – sequence: 7 givenname: Hsien-Ta surname: Hsu fullname: Hsu, Hsien-Ta organization: Division of Neurosurgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, School of Medicine, Buddhist Tzu Chi University – sequence: 8 givenname: Tz-Chuen orcidid: 0000-0003-2968-4138 surname: Ju fullname: Ju, Tz-Chuen email: tzchuen@thu.edu.tw organization: Department of Animal Science and Biotechnology, Tunghai University, National Defense Medical Center, Department of Animal Science and Biotechnology, Tunghai University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35219323$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1DAUhiNURNuBF2CBIrFhMyW-5OINUlUBrTQChGBtnTgnGY8SO9hJJXa8BgtejifhpFOqDkJVlNvJ_38-x_lPkyPnHSbJc5adMVYVryPjqpTrjHM6JVNr9Sg5YaXka54peXTv-Tg5jXGXZYLnBX-SHIucMyW4OEl-nacRezSTvcbUuq2t7eRD6tt02mL6YfP5k6By28MwQPQDphBTSEc_oZss9IsqwIjzZE0K4xg8mG3aEsHhHDy9TwvbO4KQbwrgYoeOxIOfI9K1wX5Z7XImnusm737_-BnTxkaEiE-Txy30EZ_d3lfJ13dvv1xcrjcf319dnG_WppD5tJbYFqysRM4gVy0TEgQ2KmOYIRYIRdsgZqrKGw5gpMxMQ-NLVpMKaymVWCVXe27jYafHYAcI37UHq28KPnQaAo3Yo255U7WikVVd1VLVDGQmCApoamUYrbxK3uxZ41wP2BjaqAD9AfTwi7Nb3flrXVUV56UgwKtbQPDfZoyTHmw02PfgkDZN80LInJdltfT9ci_tgFqj_-SJaBa5Pi-UkhUXsiTV2X9UdDQ4WEOZai3VDwwv7o9w1_vf2JCA7wUm-BgDtncSluklm3qfTU3Z1DfZ1Euz1T8mYydYwkHt2P5hq9hbI63jOgx65-fgKBIPuf4AGRj81w |
| CitedBy_id | crossref_primary_10_1016_j_jhep_2023_03_039 crossref_primary_10_1007_s11033_025_10852_1 crossref_primary_10_3390_genes13122385 crossref_primary_10_3839_jabc_2024_058 crossref_primary_10_1007_s10565_023_09820_x crossref_primary_10_1016_j_lfs_2024_122562 crossref_primary_10_3390_ijms26073318 crossref_primary_10_1016_j_cmet_2022_11_001 crossref_primary_10_1016_j_conb_2025_102970 crossref_primary_10_1186_s12929_024_01032_7 crossref_primary_10_1016_j_micpath_2025_107905 crossref_primary_10_3390_nu16111652 crossref_primary_10_1016_j_jphs_2025_09_003 crossref_primary_10_1007_s00210_025_04444_w crossref_primary_10_3390_ijms241210127 crossref_primary_10_1016_j_pneurobio_2022_102289 crossref_primary_10_3390_biology14020129 crossref_primary_10_3389_fnins_2022_1084493 crossref_primary_10_1002_ptr_8009 crossref_primary_10_3389_fnagi_2023_1284214 crossref_primary_10_3390_antiox13101225 crossref_primary_10_1186_s11658_023_00462_9 crossref_primary_10_1186_s40035_024_00459_0 crossref_primary_10_31083_j_jin2301002 crossref_primary_10_3390_biomedicines13020279 crossref_primary_10_3390_ijms252111787 crossref_primary_10_1007_s10787_023_01259_0 crossref_primary_10_1177_09731296241307433 crossref_primary_10_3390_ijms23158363 crossref_primary_10_1016_j_intimp_2023_110811 crossref_primary_10_1007_s11481_024_10161_7 crossref_primary_10_1002_dneu_22982 crossref_primary_10_2147_JIR_S516006 crossref_primary_10_3390_biomedicines11040999 crossref_primary_10_3390_ijms23126827 crossref_primary_10_1016_j_nbd_2024_106672 crossref_primary_10_3389_fimmu_2022_870627 crossref_primary_10_1016_j_mito_2023_10_003 crossref_primary_10_1007_s12035_024_03926_x crossref_primary_10_1016_j_neuroscience_2023_12_006 crossref_primary_10_1016_j_molimm_2022_09_002 crossref_primary_10_1016_j_neurot_2025_e00557 crossref_primary_10_1177_18796397251330144 crossref_primary_10_3390_cells11152364 crossref_primary_10_1007_s12640_024_00694_3 crossref_primary_10_3390_ijms242015340 crossref_primary_10_1016_j_neubiorev_2025_106276 crossref_primary_10_1177_18796397251338207 |
| Cites_doi | 10.1096/fj.08-122275 10.1093/hmg/ddt036 10.1016/S0006-8993(00)02082-5 10.1038/nature04516 10.1111/bph.14771 10.1097/00005072-198511000-00003 10.1002/ana.24173 10.1016/j.intimp.2020.106317 10.1038/ng0298-150 10.3390/ijms20112778 10.1083/jcb.201105010 10.1016/j.bbi.2016.12.014 10.1126/science.1184003 10.4049/jimmunol.1002657 10.4049/jimmunol.1600035 10.1186/s41232-018-0085-6 10.1186/scrt545 10.1083/jcb.200508072 10.1038/s41418-018-0124-5 10.1007/s00401-018-01957-y 10.3389/fnmol.2020.567430 10.1038/s41419-020-2565-2 10.1146/annurev.immunol.021908.132528 10.1186/s12906-020-02999-0 10.1016/j.nbd.2010.02.003 10.1186/1742-2094-7-9 10.1016/j.bbi.2014.09.011 10.1016/S0014-5793(98)01098-9 10.1056/NEJMoa1900907 10.1038/ni.1636 10.1371/journal.pone.0055375 10.1038/nn1988 10.1007/978-1-62703-523-1_1 10.1002/(SICI)1097-4644(199701)64:1<2::AID-JCB2>3.0.CO;2-1 10.1089/neu.2017.5344 10.1172/JCI43220 10.1126/scitranslmed.aah4066 10.1186/s12974-021-02111-4 10.1056/NEJM198611133152006 10.1038/s41598-018-24350-x 10.1126/science.272.5262.735 10.1016/j.bbadis.2014.06.012 10.1152/jn.2001.86.6.2667 10.1038/nm.3806 10.1038/sj.embor.7400250 10.1074/jbc.M109.083287 10.1038/ni.2919 10.1093/hmg/ddl481 10.1038/20446 10.4049/jimmunol.1003111 10.1016/S1097-2765(02)00599-3 10.1002/ana.24070 10.3389/fimmu.2015.00054 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7 10.1038/s41420-020-00293-z 10.1007/s12035-015-9152-z 10.1023/B:MEBR.0000043984.73063.d8 10.1523/JNEUROSCI.21-21-08473.2001 10.1074/jbc.273.15.9158 10.1038/s41467-019-11441-0 10.1016/0092-8674(93)90585-E 10.3389/fnmol.2019.00100 10.3791/55523 10.1016/0165-3806(94)00137-5 10.1016/j.nbd.2018.05.016 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12974-022-02419-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1742-2094 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_f2d8f3d48b8b49b1a403ac4aecb9c14a PMC8882273 A699482347 35219323 10_1186_s12974_022_02419_9 |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GrantInformation_xml | – fundername: Ministry of Science and Technology, Taiwan grantid: MOST 107-2311-B-029-002; MOST 109-2622-B-029 -001 funderid: http://dx.doi.org/10.13039/501100004663 – fundername: Ministry of Science and Technology, Taiwan grantid: MOST 107-2311-B-029-002 – fundername: Ministry of Science and Technology, Taiwan grantid: MOST 109-2622-B-029 -001 – fundername: ; grantid: MOST 107-2311-B-029-002; MOST 109-2622-B-029 -001 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c645t-4ef6178351a59f134a3ed901e0ee6ea6fdee0985d2aac440cd21941b3edeb4493 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 54 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000761951400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1742-2094 |
| IngestDate | Tue Oct 14 18:07:22 EDT 2025 Tue Nov 04 01:44:14 EST 2025 Thu Sep 04 16:23:05 EDT 2025 Tue Nov 11 10:27:12 EST 2025 Tue Nov 04 17:04:00 EST 2025 Thu Apr 03 07:09:32 EDT 2025 Sat Nov 29 04:11:18 EST 2025 Tue Nov 18 21:40:39 EST 2025 Sat Sep 06 07:29:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Huntington’s disease (HD) Interleukin‐1β (IL‐1β) Mutated huntingtin (mHTT) |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c645t-4ef6178351a59f134a3ed901e0ee6ea6fdee0985d2aac440cd21941b3edeb4493 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2968-4138 |
| OpenAccessLink | https://link.springer.com/10.1186/s12974-022-02419-9 |
| PMID | 35219323 |
| PQID | 2634527789 |
| PQPubID | 23479 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f2d8f3d48b8b49b1a403ac4aecb9c14a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8882273 proquest_miscellaneous_2634527789 gale_infotracmisc_A699482347 gale_infotracacademiconefile_A699482347 pubmed_primary_35219323 crossref_primary_10_1186_s12974_022_02419_9 crossref_citationtrail_10_1186_s12974_022_02419_9 springer_journals_10_1186_s12974_022_02419_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-26 |
| PublicationDateYYYYMMDD | 2022-02-26 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of neuroinflammation |
| PublicationTitleAbbrev | J Neuroinflammation |
| PublicationTitleAlternate | J Neuroinflammation |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | E Cattaneo (2419_CR23) 1998; 53 A Surprenant (2419_CR33) 1996; 272 JB Martin (2419_CR1) 1986; 315 G Codolo (2419_CR54) 2013; 8 F Zhu (2419_CR67) 2021; 18 M Stoffels (2419_CR48) 2015; 6 2419_CR30 RC Coll (2419_CR21) 2015; 21 B Hou (2419_CR62) 2020; 11 J Rossignol (2419_CR27) 2015; 6 YS Lin (2419_CR7) 2011; 121 S Ismael (2419_CR64) 2018; 35 VO Ona (2419_CR57) 1999; 399 E Cattaneo (2419_CR24) 1994; 83 R Allam (2419_CR32) 2011; 186 CL Wellington (2419_CR56) 1998; 273 S Ismael (2419_CR66) 2018; 8 A Halle (2419_CR53) 2008; 9 JP Vonsattel (2419_CR2) 1985; 44 S Alboni (2419_CR34) 2010; 7 DG Perregaux (2419_CR58) 2001; 299 TC Ju (2419_CR39) 2014; 1842 R Gordon (2419_CR63) 2018; 10 D Martindale (2419_CR10) 1998; 18 Q Fu (2419_CR61) 2020; 82 JY Shin (2419_CR44) 2005; 171 A Baroja-Mazo (2419_CR35) 2014; 15 C Dempsey (2419_CR60) 2017; 61 MJ Primiano (2419_CR59) 2016; 197 J Li (2419_CR36) 2014; 75 M Carmo (2419_CR50) 2019; 176 K Schroder (2419_CR15) 2010; 327 GJ Klapstein (2419_CR9) 2001; 86 M Schnaars (2419_CR17) 2013; 1040 D van Rossum (2419_CR41) 2004; 19 E Paldino (2419_CR55) 2020; 6 X Xu (2419_CR65) 2018; 117 NJ Buckley (2419_CR5) 2010 E Lee (2419_CR19) 2019; 26 M Fakhoury (2419_CR47) 2016; 53 I Olla (2419_CR52) 2020; 13 F Martinon (2419_CR12) 2002; 10 F Martinon (2419_CR14) 2006; 440 CS Lobsiger (2419_CR42) 2007; 10 DK Miller (2419_CR13) 1997; 64 FC Liu (2419_CR31) 1998; 436 DE Ribeiro (2419_CR49) 2019; 20 RM Ransohoff (2419_CR40) 2009; 27 HY Hsiao (2419_CR26) 2013; 22 JJ Siew (2419_CR25) 2019; 10 TC Ju (2419_CR11) 2011; 194 IC Stancu (2419_CR20) 2019; 137 F Perez-Severiano (2419_CR38) 2000; 862 Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM, Phase 1-2a I-HSST (2419_CR22) 2019; 380 A Nakanishi (2419_CR18) 2018; 38 C Landles (2419_CR4) 2004; 5 BK Davis (2419_CR16) 2011; 186 KH Chang (2419_CR46) 2015; 44 CJ Miedel (2419_CR29) 2017 A Di Pardo (2419_CR28) 2019; 12 2419_CR3 J Bradford (2419_CR45) 2010; 285 AD Kraft (2419_CR43) 2012; 33 H Li (2419_CR6) 2001; 21 MC Chiang (2419_CR8) 2007; 16 M Diaz-Hernandez (2419_CR51) 2009; 23 Q Ma (2419_CR37) 2014; 75 |
| References_xml | – volume: 23 start-page: 1893 year: 2009 ident: 2419_CR51 publication-title: FASEB J doi: 10.1096/fj.08-122275 – volume: 22 start-page: 1826 year: 2013 ident: 2419_CR26 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddt036 – volume: 862 start-page: 234 year: 2000 ident: 2419_CR38 publication-title: Brain Res doi: 10.1016/S0006-8993(00)02082-5 – volume: 440 start-page: 237 year: 2006 ident: 2419_CR14 publication-title: Nature doi: 10.1038/nature04516 – volume: 176 start-page: 3666 year: 2019 ident: 2419_CR50 publication-title: Br J Pharmacol doi: 10.1111/bph.14771 – volume: 44 start-page: 559 year: 1985 ident: 2419_CR2 publication-title: J Neuropathol Exp Neurol doi: 10.1097/00005072-198511000-00003 – volume: 75 start-page: 972 year: 2014 ident: 2419_CR36 publication-title: Ann Neurol doi: 10.1002/ana.24173 – volume: 82 start-page: 106317 year: 2020 ident: 2419_CR61 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106317 – volume: 18 start-page: 150 year: 1998 ident: 2419_CR10 publication-title: Nat Genet doi: 10.1038/ng0298-150 – volume: 20 start-page: 2778 year: 2019 ident: 2419_CR49 publication-title: Int J Mol Sci doi: 10.3390/ijms20112778 – volume: 194 start-page: 209 year: 2011 ident: 2419_CR11 publication-title: J Cell Biol doi: 10.1083/jcb.201105010 – volume: 61 start-page: 306 year: 2017 ident: 2419_CR60 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2016.12.014 – volume: 327 start-page: 296 year: 2010 ident: 2419_CR15 publication-title: Science doi: 10.1126/science.1184003 – volume: 186 start-page: 2714 year: 2011 ident: 2419_CR32 publication-title: J Immunol doi: 10.4049/jimmunol.1002657 – volume: 197 start-page: 2421 year: 2016 ident: 2419_CR59 publication-title: J Immunol doi: 10.4049/jimmunol.1600035 – volume: 38 start-page: 27 year: 2018 ident: 2419_CR18 publication-title: Inflamm Regen doi: 10.1186/s41232-018-0085-6 – volume: 6 start-page: 9 year: 2015 ident: 2419_CR27 publication-title: Stem Cell Res Ther doi: 10.1186/scrt545 – volume: 171 start-page: 1001 year: 2005 ident: 2419_CR44 publication-title: J Cell Biol doi: 10.1083/jcb.200508072 – volume: 26 start-page: 213 year: 2019 ident: 2419_CR19 publication-title: Cell Death Differ doi: 10.1038/s41418-018-0124-5 – volume: 137 start-page: 599 year: 2019 ident: 2419_CR20 publication-title: Acta Neuropathol doi: 10.1007/s00401-018-01957-y – volume: 13 start-page: 567430 year: 2020 ident: 2419_CR52 publication-title: Front Mol Neurosci doi: 10.3389/fnmol.2020.567430 – volume: 11 start-page: 377 year: 2020 ident: 2419_CR62 publication-title: Cell Death Dis doi: 10.1038/s41419-020-2565-2 – volume: 27 start-page: 119 year: 2009 ident: 2419_CR40 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.021908.132528 – ident: 2419_CR30 doi: 10.1186/s12906-020-02999-0 – year: 2010 ident: 2419_CR5 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2010.02.003 – volume: 7 start-page: 9 year: 2010 ident: 2419_CR34 publication-title: J Neuroinflamm doi: 10.1186/1742-2094-7-9 – volume: 44 start-page: 121 year: 2015 ident: 2419_CR46 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2014.09.011 – volume: 436 start-page: 92 year: 1998 ident: 2419_CR31 publication-title: FEBS Lett doi: 10.1016/S0014-5793(98)01098-9 – volume: 380 start-page: 2307 year: 2019 ident: 2419_CR22 publication-title: N Engl J Med doi: 10.1056/NEJMoa1900907 – volume: 9 start-page: 857 year: 2008 ident: 2419_CR53 publication-title: Nat Immunol doi: 10.1038/ni.1636 – volume: 8 start-page: e55375 year: 2013 ident: 2419_CR54 publication-title: PLoS ONE doi: 10.1371/journal.pone.0055375 – volume: 10 start-page: 1355 year: 2007 ident: 2419_CR42 publication-title: Nat Neurosci doi: 10.1038/nn1988 – volume: 1040 start-page: 1 year: 2013 ident: 2419_CR17 publication-title: Methods Mol Biol doi: 10.1007/978-1-62703-523-1_1 – volume: 64 start-page: 2 year: 1997 ident: 2419_CR13 publication-title: J Cell Biochem doi: 10.1002/(SICI)1097-4644(199701)64:1<2::AID-JCB2>3.0.CO;2-1 – volume: 35 start-page: 1294 year: 2018 ident: 2419_CR64 publication-title: J Neurotrauma doi: 10.1089/neu.2017.5344 – volume: 299 start-page: 187 year: 2001 ident: 2419_CR58 publication-title: J Pharmacol Exp Ther – volume: 121 start-page: 1519 year: 2011 ident: 2419_CR7 publication-title: J Clin Invest doi: 10.1172/JCI43220 – volume: 10 start-page: eaah4066 year: 2018 ident: 2419_CR63 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aah4066 – volume: 18 start-page: 66 year: 2021 ident: 2419_CR67 publication-title: J Neuroinflammation doi: 10.1186/s12974-021-02111-4 – volume: 315 start-page: 1267 year: 1986 ident: 2419_CR1 publication-title: N Engl J Med doi: 10.1056/NEJM198611133152006 – volume: 8 start-page: 5971 year: 2018 ident: 2419_CR66 publication-title: Sci Rep doi: 10.1038/s41598-018-24350-x – volume: 272 start-page: 735 year: 1996 ident: 2419_CR33 publication-title: Science doi: 10.1126/science.272.5262.735 – volume: 1842 start-page: 1668 year: 2014 ident: 2419_CR39 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbadis.2014.06.012 – volume: 86 start-page: 2667 year: 2001 ident: 2419_CR9 publication-title: J Neurophysiol doi: 10.1152/jn.2001.86.6.2667 – volume: 21 start-page: 248 year: 2015 ident: 2419_CR21 publication-title: Nat Med doi: 10.1038/nm.3806 – volume: 5 start-page: 958 year: 2004 ident: 2419_CR4 publication-title: EMBO Rep doi: 10.1038/sj.embor.7400250 – volume: 285 start-page: 10653 year: 2010 ident: 2419_CR45 publication-title: J Biol Chem doi: 10.1074/jbc.M109.083287 – volume: 15 start-page: 738 year: 2014 ident: 2419_CR35 publication-title: Nat Immunol doi: 10.1038/ni.2919 – volume: 16 start-page: 483 year: 2007 ident: 2419_CR8 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddl481 – volume: 33 start-page: e17 issue: 621 year: 2012 ident: 2419_CR43 publication-title: Neurobiol Aging – volume: 399 start-page: 263 year: 1999 ident: 2419_CR57 publication-title: Nature doi: 10.1038/20446 – volume: 186 start-page: 1333 year: 2011 ident: 2419_CR16 publication-title: J Immunol doi: 10.4049/jimmunol.1003111 – volume: 10 start-page: 417 year: 2002 ident: 2419_CR12 publication-title: Mol Cell doi: 10.1016/S1097-2765(02)00599-3 – volume: 75 start-page: 209 year: 2014 ident: 2419_CR37 publication-title: Ann Neurol doi: 10.1002/ana.24070 – volume: 6 start-page: 54 year: 2015 ident: 2419_CR48 publication-title: Front Immunol doi: 10.3389/fimmu.2015.00054 – volume: 53 start-page: 223 year: 1998 ident: 2419_CR23 publication-title: J Neurosci Res doi: 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7 – volume: 6 start-page: 69 year: 2020 ident: 2419_CR55 publication-title: Cell Death Discov doi: 10.1038/s41420-020-00293-z – volume: 53 start-page: 2778 year: 2016 ident: 2419_CR47 publication-title: Mol Neurobiol doi: 10.1007/s12035-015-9152-z – volume: 19 start-page: 393 year: 2004 ident: 2419_CR41 publication-title: Metab Brain Dis doi: 10.1023/B:MEBR.0000043984.73063.d8 – volume: 21 start-page: 8473 year: 2001 ident: 2419_CR6 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.21-21-08473.2001 – volume: 273 start-page: 9158 year: 1998 ident: 2419_CR56 publication-title: J Biol Chem doi: 10.1074/jbc.273.15.9158 – volume: 10 start-page: 3473 year: 2019 ident: 2419_CR25 publication-title: Nat Commun doi: 10.1038/s41467-019-11441-0 – ident: 2419_CR3 doi: 10.1016/0092-8674(93)90585-E – volume: 12 start-page: 100 year: 2019 ident: 2419_CR28 publication-title: Front Mol Neurosci doi: 10.3389/fnmol.2019.00100 – year: 2017 ident: 2419_CR29 publication-title: J Vis Exp doi: 10.3791/55523 – volume: 83 start-page: 197 year: 1994 ident: 2419_CR24 publication-title: Brain Res Dev Brain Res doi: 10.1016/0165-3806(94)00137-5 – volume: 117 start-page: 15 year: 2018 ident: 2419_CR65 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2018.05.016 |
| SSID | ssj0032562 |
| Score | 2.5327523 |
| Snippet | Background
Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the
huntingtin
(
HTT
) gene. When the number... Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG... Background Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of... Abstract Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 56 |
| SubjectTerms | Animals Biomedical and Life Sciences Biomedicine Disease Models, Animal Genetic aspects Huntington Disease - drug therapy Huntington Disease - genetics Huntington Disease - metabolism Huntington's chorea Huntington’s disease (HD) Immunology Inflammasomes - therapeutic use Interleukin‐1β (IL‐1β) Male Mice Mice, Transgenic Mutated huntingtin (mHTT) Neurobiology Neurodegenerative Diseases Neurology Neuroprotection Neurosciences NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Patient outcomes Prevention |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJtAQUZC4gBR49jx47ggqh7KqkKAerNsZ6Ku1GarTeDM3-DAn-OXMHaS1aZI5cI1Hmcdz3ge65lvCHlVKl-xBlxuoMQApWY-96pBhjDFXJAqQKqF-Xqslkt9empOdlp9xZywAR542LiDpqx1w2uhvfbCeOZEwV0QDoI3gYnkGqHXMwVTgw7maMjLqURGy4MOrZoSecxcR5vETG5mZiih9f-tk3eM0tWEySu3pskYHd4ld0Yvki6G1d8jN6C9T259HO_JH5BfC9qlBjeoy-iqPVt5PLgbum4o-nt0efzphOPjBqXhwnXrC6Cuo45ervuYO4Qv3qnKohPqOEX3lib4yxHbATmKL8F5fbR3KIhIHP9IAJra68RfOxoaUaB_-fvHz46Ot0EPyZfDD5_fH-VjI4Y8SFH1uYAmVhLyirnKNIwLx6FGRwIKAAlONjVAYXRVlw5ZI4pQox4UzCMVeCEMf0T22nULTwhVwCoFsqiNiFCDHsM90NwZLVxVhWAywia-2DCilMdmGec2RSta2oGXFnlpEy8tznmznXM5YHRcS_0usntLGfG10wOUOjtKnf2X1GXkdRQWG7UALi-4sZgBPzLiadmFNEbokguVkf0ZJZ7eMBt-OYmbjUMx5a0F5JUtJRdVqZTGFT8exG-7ZvSao-PNM6Jmgjn7qPlIuzpL4OEaQyp0WTPydhJhO2qt7ppNe_o_Nu0ZuV0ORzAv5T7Z6zff4Dm5Gb73q27zIh3gP9WFTXY priority: 102 providerName: Directory of Open Access Journals |
| Title | A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease |
| URI | https://link.springer.com/article/10.1186/s12974-022-02419-9 https://www.ncbi.nlm.nih.gov/pubmed/35219323 https://www.proquest.com/docview/2634527789 https://pubmed.ncbi.nlm.nih.gov/PMC8882273 https://doaj.org/article/f2d8f3d48b8b49b1a403ac4aecb9c14a |
| Volume | 19 |
| WOSCitedRecordID | wos000761951400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: RBZ dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: DOA dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: M~E dateStart: 20040101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1742-2094 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0032562 issn: 1742-2094 databaseCode: RSV dateStart: 20041201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoixAX3o-FsjISEgeIWMdObB-3qFWR2tVqgWo5WbYzoSvRbLVZOPM3OPDn-CWMnWTVFFQJLpESjxM_5uV45jMhL1LpMlaCTTSkuEApmEucLHFCmGTW59JDzIU5OZKTiZrP9bRNCqu7aPduSzJq6ijWKn9To2WSIgnR52hXmE70FtlBc6eCOM7en3T6l6MRT7v0mL_W65mgiNT_pz6-YJAuB0te2jGNhujg9v914Q651TqedNxwyl1yDap75MZxu7V-n_wc0zqeiYPqjy6q04VDWV_RZUnRRaSTo9mU4-MSGejM1sszoLamlp4v1yHcCF98IZGLdkDlFD1iGhEzWzgIZAJ8CdZbBxOJvIvE4d8D0HgiT_jaYXN2Bbqkv77_qGm7gfSAfDzY__D2MGnPbkh8LrJ1IqAMyYc8YzbTJePCcijQ94ARQA42LwsAnLusSK31Qox8gapTMIdU4ITQ_CHZrpYVPCZUAssk5KNCi4BO6HCFCIpbrYTNMu_1gLBuOo1vgc3D-RpfTFzgqNw0425w3E0cd4N1Xm3qnDewHldS7wUu2VAGSO74YLn6bFoJN2VaqJIXQjnlhHbMihHHrlnwTnsm7IC8DDxmguLA5nnb5j9gJwMElxnnWguVciEHZLdHiQLve8XPOy41oShEyVWAc2XSnIsslVJhix81XLtpMzrawVfnAyJ7_NzrVL-kWpxGvHGFqzD0cgfkdcfVplV09RWD9uTfyJ-Sm2kjGEma75Lt9eorPCPX_bf1ol4NyZacy3hVQ7Kztz-Zzobx9wneTd8dTz8Now74DckKVko |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIMqFdyFQwEhIHCBiHTuxfVwQ1SK2q6qUqjfLdiZ0JZqtNgtn_gYH_hy_hLGTrJqCKsE1Hid-fPNwPA9CnmfS5awCm2rI8IBSMpc6WeGGMMmsL6SHGAtzOJWzmTo60ntdUFjTe7v3V5JRUke2VsXrBjWTFGnwPke9wnSqL5MrAjVWcOTb_3jYy1-OSjzrw2P-2m-ggmKm_j_l8RmFdN5Z8tyNaVREOzf_bwq3yI3O8KTjFim3ySWo75Bru93V-l3yc0ybWBMHxR-d18dzh7y-pIuKoolIZ9P9PY6PKwTQiW0WJ0BtQy09XayCuxG--EwgF-0TlVO0iGnMmNmlg0AQ4Euw3yqoSMQuEod_D0BjRZ7wtUlbuwJN0l_ffzS0u0C6Rz7tvDt4O0m72g2pL0S-SgVUIfiQ58zmumJcWA4l2h4wAijAFlUJMNIqLzNrvRAjX6LoFMwhFTghNN8iG_WihgeESmC5hGJUahGyEzo8IYLiVith89x7nRDWb6fxXWLzUF_ji4kHHFWYdt0NrruJ626wz8t1n9M2rceF1G8CStaUISV3fLBYfjYdh5sqK1XFS6GcckI7ZsWI49QseKc9EzYhLwLGTBAcODxvu_gHnGRIwWXGhdZCZVzIhGwPKJHh_aD5WY9SE5qCl1wNuFcmK7jIMykVjvh-i9r1mNHQDrY6T4gc4HkwqWFLPT-O-cYVnsLQyk3Iqx7VphN0zQWL9vDfyJ-SzcnB7tRM388-PCLXs5ZJ0qzYJhur5Vd4TK76b6t5s3wSuf03iDBTHg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgQSsuvBcKCxgJiQNEW8dObB_Lo1pEqSoeq71ZtjNhK7Fp1RTO_A0O_Dl-CWMnqZoFrYS4xuPEj88z49jzDSFPUukyVoJNNKS4QSmYS5wscUKYZNbn0kOMhTmayOlUHR_r2VYUf7zt3h1JNjENgaWpWh8si7JZ4io_qNFKSZGEm-hoY5hO9EVySYSkQWG__uGo08UcDXrahcr8tV7PHEXW_j9185ZxOntx8szpaTRK42v_353r5GrrkNJRg6Ab5AJUN8nuu_bI_Rb5OaJ1zJWDapHOq5O5Qx2woouSoutIp5P3M46PSwTWqa0Xp0BtTS1dLsLnEdt0K8CLdgTmFD1lGpk0W5oIBAe-BOutg-lETKNw-CcBNGbqCV87bHJaoKv66_uPmrYHS7fJp_Hrjy8PkzanQ-Jzka0TAWUISuQZs5kuGReWQ4E-CQwBcrB5WQAMtcqK1FovxNAXqFIFcygFTgjN98hOtajgLqESWCYhHxZaBNZChztHUNxqJWyWea8HhHVTa3xLeB7ybnwxceOjctOMu8FxN3HcDdZ5tqmzbOg-zpV-ERCzkQxU3fHBYvXZtCvflGmhSl4I5ZQT2jErhhy7ZsE77ZmwA_I04M0EhYLN87aNi8BOBmouM8q1FirlQg7Ifk8SFYHvFT_uEGtCUbg9VwHOlUlzLrJUSoUtvtMgeNNmdMCDD88HRPaw3etUv6San0QecoW7M_R-B-R5h3DTKsD6nEG792_ij8ju7NXYTN5M394nV9JmjSRpvk921quv8IBc9t_W83r1MC7830vzXAI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+selective+inhibitor+of+the+NLRP3+inflammasome+as+a+potential+therapeutic+approach+for+neuroprotection+in+a+transgenic+mouse+model+of+Huntington%E2%80%99s+disease&rft.jtitle=Journal+of+neuroinflammation&rft.au=Chen%2C+Kai-Po&rft.au=Hua%2C+Kuo-Feng&rft.au=Tsai%2C+Fu-Ting&rft.au=Lin%2C+Ting-Yu&rft.date=2022-02-26&rft.issn=1742-2094&rft.eissn=1742-2094&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12974-022-02419-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12974_022_02419_9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon |